Lantheus Medical Imaging of North Billerica, MA, has acquired the balance of the worldwide rights for gadofosveset trisodium, an injectable MR angiography (MRA) blood-pool imaging agent.
The company currently markets the imaging agent as Ablavar, which is indicated for use in adults with known or suspected peripheral vascular disease to evaluate aortoiliac occlusive disease.
Lantheus purchased the worldwide rights in a recent auction of the remaining assets of now-defunct contrast developer Epix Pharmaceuticals. Lantheus already owns exclusive rights to Ablavar in the U.S., Canada, and Australia.
Terms of the purchase were not disclosed.
Related Reading
Lantheus, MDS Nordion sign Mo-99 deal, July 8, 2010
MDS Nordion, Guerbet to develop PET agents, June 24, 2010
Lantheus touts Definity safety data, June 16, 2010
Lantheus' F-18 PET agent shows good dosing ratio, June 11, 2010
Lantheus touts results for PET agent at SNM, June 8, 2010
Copyright © 2010 AuntMinnie.com
.fFmgij6Hin.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=100&w=100&auto=format%2Ccompress&q=70)
.fFmgij6Hin.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=167&w=250&auto=format%2Ccompress&q=70)
